anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
FIELD: medicine. SUBSTANCE: proposed solid non-porous sustained-effect microspheres have diameter 5-300 mcm and contain at least one pharmaceutically active substance enclosed into spherical envelope formed by at least one pharmaceutically inert carrier substance. Latter is naturally present in recipient&#39;s organism, remains stable in solid state up to at least 60 C, and is dissolved by recipient physiological medium at slower pace than pharmaceutically active principle. Proposed method for preparing said microspheres comprises following steps of: melting down pharmaceutically inert carrier substance, dispersing pharmaceutically active principle into melt in inert atmosphere, pulverizing dispersion thus-obtained in form of mist in freezing chamber under pressure in inert atmosphere at temperatures ranging from -15 C up to -50 C, separating resultant microspheres into fractions according to their sizes. Proposed suspension intended for administration by parenteral injection comprises effective amount of said microspheres distributed in pharmaceutically acceptable liquid vehicle, said pharmaceutically active principle being insoluble in said liquid vehicle. EFFECT: novel microspheres make it possible to retard and prolong curative effect of active agents which are too fast dissolved in physiological medium agents acting upon central or vegetative nervous system, such as vasodilative and antihistaminic agents, hormones, contraceptives. 16 cl, 13 dwg
PROBLEM TO BE SOLVED: To provide a mineral absorption-stimulating composition effective as an ingredient for stimulating the absorption of calcium in intestinal tracts, and to provide a mineral absorption stimulating additive, especially a calcium absorption-stimulating additive, which can be used for foods, feeds, medicines, and so on. SOLUTION: This mineral absorption-stimulating composition contains high mol.wt. chitin, especially chitin having an average mol.wt. of &gt;= 200,000, and/or high mol.wt. chitosan, preferably chitosan having an average mol.wt. of &gt;=10,000, as active ingredients, and, if necessary, further contains a calcium salt as an active ingredient. The mineral is preferably calcium.
A preparation method of a core-shell structure gastric retention hydrogel capable of realizing drug sustained release belongs to the technical field of soft material and pharmaceutical preparation. Firstly, dissolving acrylamide, N&#39; -bis (acryloyl) cystamine, chitosan, sodium alginate, tetramethylethylenediamine and ammonium persulfate in an aqueous solution containing ethanol, heating the mixed solution in a mold to form a first network gel, soaking the first network gel in an aqueous solution of hydrochloric acid, and washing the first network gel in deionized water to obtain a double-network hydrogel shell, wherein the shell rapidly swells in gastric juice and stays in the stomach to prolong the residence time in the body. Secondly, drug-loaded hydrogel cores were prepared. And finally, placing the drug-loaded core in a double-network hollow hydrogel shell, and sealing the edge by using a biological adhesive to obtain the drug-loaded core-shell structure hydrogel. The core-shell structure can prolong the release path of the drug, thereby prolonging the release time of the drug. The preparation process is simple and controllable, and is easy to scale; the drug loading rate of the prepared core-shell hydrogel can reach 100%, and drug waste is avoided.
A system and method for providing food and drink through widespread food outlets, wherein each food outlet comprises a plurality of automated machines for making and providing food/drink/cake/food-supplement items with specified instructions. The food outlet further comprises pick-up lockers for storing the prepared items. The food outlet further comprises transporters for transporting the prepared items to the pick-up lockers. The transporters can be persons or robots. Each automated machine is controlled, managed and monitored by a control server. A customer with a mobile device initiates an order request of an item selected from: food, drink, cake and food supplement items, and the selected item is to be made/produced with a recipe selected from: (a) an existing recipe, (b) a specific recipe self-created by the customer using a provided recipe creator/generator, (c) a specific recipe created based on information filled in through a provided form on the mobile device, and (d) a specific recipe created based on medical data obtained with a wearable device. The server receives the order request and prepares a specification associated with the ordered item, the specification comprises an item identifier, an item recipe, an item quantity and a time- and-date for preparing the item. The server selects an automated machine associated with the ordered item, and then instructs the selected machine to prepare the ordered item according to the specification. The prepared item is transported to a pick-up locker, and finally, the customer is notified to pick up the prepared item at the pick-up locker. At the customer&#39;s choice, a courier service can be notified to pick up the prepared item at the pick-up locker for a delivery to a designated address.
NEW MATERIAL:The compound of formula I (R&lt;1&gt; is lower alkyl). EXAMPLE:alpha-(N-ethyl-N-methylenecarboxy)amino-2,6-acetoxylidide hydrochloride. USE:A local anesthetic useful in operation, nerve block and pain clinic necessary for medical treatment. The anesthetic period is thrice that of the conventional anesthetic. PREPARATION:The compound of formula I can be produced by mixing and heating a compound of formula II (or its acid anhydride, active ester, acid halide, etc.) with 2,6-xylidine in the absence of solvent or in an inert solvent (e.g. chloroform, dichloroethane or THF). The compound of formula I has development and strength of anesthetic action comparable to those of lidocaine.
Preventing Ant Tray can be used as a normal tray. When you have left over from a meal or fruit, you can put them on the Preventing Ant Tray, and then put the cover on it. It can not only prevent the ant to eat your food, but also can put the fly or cockroach crawl over your food to pollute your food. When using, just pour water on the Preventing Ant Tray, and put the cover on. Then the Preventing Ant Tray is finished. Otherwise, when taking the cover off, it can be placed under the Preventing Ant Tray. It can add the Preventing Ant Tray&#39;s height and make it look more beautiful.
1345358 Anti-inflammatory preparations A H ROBINS CO Inc 8 Nov 1971 [16 Nov 1970] 51726/71 Heading A5B Anti-inflammatory preparations effective in preventing gastric irritation and bleeding of the gastric mucosa comprise a coprecipitate of an anti-inflammatory agent, such as aspirin, phenylbutazone or indomethacin, and a lignosulphonic acid or a salt thereof such as the ammonium, sodium, potassium, calcium, magnesium or lithium salt. The coprecipitate may be formed by acidifying an aqueous basic solution of an anti-inflammatory agent and a lignosulphonate and isolating the coprecipitate, e.g. by filtration or by spray drying. Pharmaceutical compositions for oral administration in the form of tablets or capsules comprise the coprecipitate and a carrier. The coprecipitate may comprise from 2 to 10% by weight of lignosulphonate. Suitable lignosulphonates are methanol-soluble or are those sold under the Trade Mark &#34;Peritan&#34;.
A medical information retrieval system includes a natural language processing system that processes voice user queries to identify keywords and phrases. These keywords and phrases are provided to an inference engine that provides a set of knowledge-based inferences from a medical knowledge source based on the keywords and phrases. These knowledge-based inferences are then provided to an information retrieval engine that retrieves a corresponding plurality of medical articles based on the knowledge-based inferences and ranks each medical article with respect to the knowledge-based inferences. The summarization engine receives the ranked articles and creates a model based on the topic keywords and candidate sentences found in the highly ranked articles. The paraphrasing engine processes the candidate sentences to provide a summary response according to a knowledge-based paraphrasing model. The audio output device presents the summary report as a response to the user&#39;s original voice query.
NEW MATERIAL:A compound shown by the formula. USE:A drug and an agricultural chemical. A lipid compound of spermidine bonded to a fatty acid by amide bond in a cell of bacterium. PREPARATION:A bacterium belonging to the genus Acetobacter or Gluconobacter is cultured in a medium at pH &lt;=5 and a culture mixture is extracted with an organic solvent such as methanol. Then the extract is purified by column chromatography to give a compound shown by formula. The fatty acid having amide bond is obtained by hydrolyzing a compound shown by the formula with hydrochloric acid and subjecting to gas chromatography or the fatty acid having ester bond is obtained by decomposing the compound shown by the formula with a weak alkali, converting to a methyl ester derivative and subjecting to gas chromatography.
Methods are provided for conducting surgical procedures in a patient wherein, during the surgical procedure, autonomous ventricular electrical conductivity and escape beats are reversibly and transiently suppressed to facilitate the surgical procedure. Also provided are compositions which are capable of inducing ventricular asystole in a patient. The compositions may include an AV node blocker. In one embodiment, compositions including an atrioventricular (AV) node blocker and a  beta -blocker are provided, wherein the  beta -blocker is present in an amount sufficient to substantially reduce the amount of AV node blocker required to induce ventricular asystole in the patient. The compositions and methods may be used for inducing temporary ventricular asystole in a beating heart, and to facilitate the performance of a variety of surgical techniques, including minimally invasive microsurgical techniques. Methods for performing a surgical procedure on a human patient are provided wherein a composition capable of inducing transient reversible ventricular asystole is administered to the heart, for example by intracoronary injection. The heart then is electrically paced using an electrical pacing system, thereby to maintain the patient&#39;s blood circulation. The electrical pacing then is selectively intermittently stopped to allow ventricular asystole to occur, and the steps of the surgical or therapeutic procedure, such as suturing, are conducted during the time that the electrical pacing is intermittently stopped. The methods and compositions advantageously may be used in a range of different surgical procedures including cardiac, vascular and neurosurgical procedures.
PURPOSE: A Cuscuta japonica Chois. extract is provided to suppress osteoclast differentiation(suppression of TRAP(+) multinucleate cell generation), and expression of genes such as cathepsin K, TNFalpha, and IL-6, and to be used as a pharmaceutical composition for suppressing osteoporosis. CONSTITUTION: A pharmaceutical composition for preventing and treating metabolic bone diseases contains a Cuscuta japonica Chois. extract as an active ingredient. The metabolic bone diseases are osteoporosis, Paget&#39;s disease, periodontal disease, metastatic cancer, or rheumatoid arthritis. The extract contains 0.01-99wt% of a crude drug extract.
In one embodiment, the present invention is directed to a first oligonucleotide comprising the sequence of or derived from 5&#39;-CTAGGGCGGGCGGGACTCACCTAC-3&#39; or the nucleic acid sequence complementary thereto. The first oligonucleotide can be used with a nucleic acid of between 15 and 30 nucleotides that does not comprise the sequence of the first oligonucleotide and is found in the region from Vbeta to Jbeta of the Vbeta13.1 gene in Vbeta13.1 T cells, wherein the sequences of the oligonucleotide and the nucleic acid are not found on the same strand of the Vbeta13.1 gene pair, to amplify a portion of the Vbeta13.1 gene. Alternatively, the first oligonucleotide can be used with a labeling moiety in methods of detecting a LGRAGLTY motif found in T cell receptors of Vbeta13.1 T cells. This motif is associated with autoimmune diseases, such as multiple sclerosis (MS). Once the motif is detected, the autoimmune disease can be treated or its progress monitored. The autoimmune disease can be treated by administering a peptide comprising the LGRAGLTY motif.
A macroencapsulation device for somatic cells using ultrapurified Na alginate and polysulfone hollow fibers of 30 kDa molecular weight cutoff. Ultrapurified Na alginate material is used which has a high `G` content, low endotoxin content, low divalent metal toxins and low protein impurities. Islet cells prior to being encapsulated, are irrigated with Hank&#39;s modified solution (without Ca and Mg) containing gentamycin, vancomycin and amphotericin B and then passed through a leukoabsorb filter to reduce the donor antigen load of passenger leukocytes and to reduce the bioburden of microorganisms including viruses. Encapsulation is done in RPMI 1640 tissue culture fluid containing necessary nutritional supplements and ATP source of energy. The open ends of the fiber are covered with a porous membrane. To further improve biocompatibility, the outer wall of the polysulfone is lightly gelled with alginate gel. Such double gelled, encapsulated fibers do not affect diffusion of glucose or insulin across the hollow fibers.
&lt;P&gt;PROBLEM TO BE SOLVED: To prepare a hair shampoo containing fatty acid soap as a main detergent and hardly imparting squeaky feeling to the hair after shampooing.  &lt;P&gt;SOLUTION: This hair shampoo contains (1) 5-20 mass% clay mineral. Preferably, the clay mineral is mica. More preferably, the mica contains two kinds of aluminum fluoromagnesium sodium silicate and aluminum fluoromagnesium potassium silicate. The shampoo preferably contains a potassium soap of a fatty acid as a detergent component.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE: To obtain a nonaerosol type foamy composition for the oral cavity, filled in a nongas atmospheric-pressure container, foamable in use, applicable to brushing, excellent in dispersibility in the oral cavity and containing no polishing agent blended therein. CONSTITUTION: This foamy composition for the oral cavity contains &gt;=0.2wt.% anionic surfactant (e.g. sodium laurylsulfate), 0.1-5wt.% nonionic surfactant (e.g. an alkyl fatty acid diethanolamide) or amphoteric surfactant (e.g. an alkylbetaine) and a viscous agent (e.g. a polyhydric alcohol) and/or a binder (e.g. hydroxyethyl cellulose) and further, as necessary, a perfume, a sweetener, a coloring matter, a preservative, a pharmacodynamically effective agent, ethanol, etc., blended therewith. At this time, the viscosity at 25 deg.C is kept at &lt;=7P, preferably 0.05-1P and the composition for the oral cavity is filled in a nonaerosol type nongas atmospheric-pressure container for applying a pressure to the contents, mixing the contents with air and jetting the contents into a foamy shape by jetting thereof to afford the objective material.
PCT No. PCT/RO95/00010 Sec. 371 Date Feb. 10, 1997 Sec. 102(e) Date Feb. 10, 1997 PCT Filed Aug. 15, 1995 PCT Pub. No. WO96/06048 PCT Pub. Date Feb. 29, 1996An apparatus is disclosed for obtaining inhibitively active &#34;I&#34; water and stimulatively activated &#34;S&#34; water which comprises: a parallelipipedic column having an open top; a support for said column; a cover closing said top of said column; at least one electrode assembly in said column and including: a pair of spaced apart mutually parallel porous membranes defining between inner surfaces thereof a supply space receiving water to be separated into inhibitively activated &#34;I&#34; water and stimulatively activated &#34;S&#34; water, respective porous electrodes spaced from outer surfaces of said membranes and parallel thereto, and a respective spacer between each of said electrodes and the respective outer surface whereby water flows outwardly from said supply space through said membranes and said electrodes; means for electrically connecting one of said electrodes as a positive electrode and the other of said electrodes as a negative electrode; means in said column for forming a first storage space adjacent said positive electrode for collecting said I-water and a second storage space adjacent said negative electrode for collecting said S-water; and respective outlets formed in said column and communicating with said storage spaces for respectively discharging said I-water and said S-water.
The present invention provides methods, systems, and compositions for ARMM-mediated delivery of molecules of interest (e.g., therapeutic agents) to cells and tissues of the eye. The present invention further relates to compositions and methods of producing, testing, and administering ARRDC1-mediated microvesicles (&#34;ARMMs&#34;) to internal structures of the eye. More particularly, the present invention provides compositions and methods of producing, testing, and administering ARMMs particles comprising one or more therapeutic agents (e.g., biological molecules including, but not limited to, CRISPR/Cas9 and other similar endonucleases, base editors, small molecules, proteins, and nucleic acids (e.g., DNA, RNA, siRNA, mRNA, miRNA, and the like)). Also provided are methods of administering therapeutic agents associated with ARMMs, including, but not limited to, methods of treating or contacting cells and tissues of the eye in one or more dosing regimens. In particular, the present invention provides methods of administering therapeutic agents via ARMMs to the cells and tissues that comprise the retina or into the subretinal space. Additionally, the present invention relates to methods of manufacturing (e.g., culturing, clarifying, separating, and concentrating) the inventive compositions from stable producer cell lines and from cell cultures.
Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient&#39;s calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient&#39;s anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g., electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal sympathetic nerve.
The present invention provides methods for introducing functional peptides into organelles. Additionally, the present invention provides a method for correcting a phenotypic deficiency in a mammal that results from a mutation in the mammal&#39;s mitochondrial DNA (mtDNA). The present invention further provides a method for treating a mitochondrial disorder in a subject in need of treatment therefor. Also provided is an expression vector that is useful for introducing a functional peptide encoded by an mtDNA sequence into a mitochondrion. The present invention also provides eukaryotic cells transformed by expression vectors that are useful for introducing functional peptides into organelles. Finally, the present invention provides a pharmaceutical composition comprising a non-nuclear nucleic acid sequence encoding a peptide for introduction into an organelle, a nucleic acid sequence encoding an organelle-targeting signal, and a pharmaceutically-acceptable carrier.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an image search system for efficiently searching medical images stored in a plurality of image storage servers.  &lt;P&gt;SOLUTION: An operator operates an image viewer 3a to input the search conditions of image data to be searched, and to simultaneously designate a search destination group. The search destination group is selected from among image storage devices(image storage devices installed in another image viewer, image server and modality or the like) connected to the image viewer 3a. Also, the priority of the image storage devices(image storage devices installed in the other image viewer, image server and modality or the like) is set in the image viewer 3a, and when the same image data are searched, only the image data of the image storage device whose priority is the highest are displayed. The operator can obtain the target image data in a single search operation without considering the location of the image data or communication system(original communication 25 or DICOM communication 23).  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To obtain a compound useful as an intermediate for antihypertensive agent, an antiasthmatic agent, etc., by reacting a pyridinecarboxylic acid ester with a lactone in the presence of a base and then subjecting the resultant compound to decarboxylating reaction under heating conditions. CONSTITUTION:A compound of formula I (R&lt;1&gt; is lower alkyl, cycloalkyl, cycloether, aryl, aralkyl, etc.) (e.g. a nicotinic acid ester) is made to react with a compound of formula II [R&lt;2&gt; is H, halogen, lower alkyl, aryl, cyano, etc.; (p) is 2-5] (e.g. 8-valerolactone) in the presence of a base (e.g. potassium t- butoxide), as necessary, in a solvent at -20 deg.C to the refluxing temperature of the solvent. The resultant reactional product is then thermally refluxed and subjected to decarboxylating reaction to afford the objective compound of formula III. The reaction can be carried out by using the inexpensive readily available raw material under mild reactional conditions. 5-Oxo-5-(3-pyridyl)-1-pentanol can be exemplified as the compound of formula III.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an anti-allergic agent safe as compared with synthetic compounds from aspects of adverse effects, etc., suppressing a reaction in a stage before liberation of a mediator and suitable for prophylaxis of allergic diseases.  &lt;P&gt;SOLUTION: The anti-allergic agent and anti-allergic composition comprise a soybean fermented product obtained by fermenting soybeans in a state of ≤5 wt.% of common salt or a salt-free state with any one or more of a fungus (e.g. the genus Aspergillus), a yeast (e.g. the genus Zygosaccharomyces) and a lactic acid bacterium. Thereby, the anti-allergic agent has no adverse effect by excessive ingestion of salt.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
Use of salicin for cosmetic or dermatological use and/or prevention of irritative and/or erythematous skin appearance is claimed. Also claimed is use of salicin to treat `stinging&#39;, atopical dermatitis and type I and IV skin allergies, and to raise the threshold of sensitive skin. Pref. erythematous skin appearance caused by unclean skin or acne vulgaris, esp. inflammed comedones, nappy rash, inflammed skin in the mouth and nose area, herpes labialis, sunburn and light skin cracks. Glucoside concn. in prepn. is 0.01-10 (pref. 0.1-5, most pref. 0.2-2.0) wt.%.